Chengdu Easton Biopharmaceuticals Co (SHSE:688513) EBIT: ¥287 Mil (TTM As of Mar. 2026)


SHSE:688513 Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
95 GF Score
Price ¥52.66
GF Value ¥47.90
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Chengdu Easton Biopharmaceuticals Co EBIT?

Chengdu Easton Biopharmaceuticals Co SHSE:688513 -4.43% 95 EBIT is ¥287 Mil as of Mar. 2026. GuruFocus rates SHSE:688513 with a GF Score™ of 95/100 and a GF Value™ of ¥47.90 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Chengdu Easton Biopharmaceuticals Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ¥48 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ¥287 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Chengdu Easton Biopharmaceuticals Co's annualized ROC % for the quarter that ended in Mar. 2026 was 8.34%. Chengdu Easton Biopharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 15.75%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Chengdu Easton Biopharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.38%.

Chengdu Easton Biopharmaceuticals Co  (SHSE:688513) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Chengdu Easton Biopharmaceuticals Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=162.284 * ( 1 - 8.69% )/( (1809.172 + 1743.256)/ 2 )
=148.1815204/1776.214
=8.34 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3797.879 - 475.24 - ( 1613.432 - max(0, 618.697 - 2132.164+1613.432))
=1809.172

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3777.445 - 470.453 - ( 1621.53 - max(0, 553.638 - 2117.374+1621.53))
=1743.256

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Chengdu Easton Biopharmaceuticals Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=191.908/( ( (1224.2 + max(-61.658, 0)) + (1212.575 + max(-43.931, 0)) )/ 2 )
=191.908/( ( 1224.2 + 1212.575 )/ 2 )
=191.908/1218.3875
=15.75 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(181.288 + 228.706 + 31.931) - (475.24 + 0 + 28.343)
=-61.658

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(177.991 + 246.66 + 35.277) - (470.453 + 0 + 33.406)
=-43.931

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Chengdu Easton Biopharmaceuticals Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=287.008/8491.862
=3.38 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Easton Biopharmaceuticals Co EBIT Related Terms

Chengdu Easton Biopharmaceuticals Co EBIT Historical Data

* Premium members only.

The historical data trend for Chengdu Easton Biopharmaceuticals Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chengdu Easton Biopharmaceuticals Co EBIT Chart

Chengdu Easton Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 247.28 264.59 245.06 256.27 302.16

Chengdu Easton Biopharmaceuticals Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.13 87.88 92.97 58.18 47.98

SHSE:688513 vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Chengdu Easton Biopharmaceuticals Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Chengdu Easton Biopharmaceuticals Co EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chengdu Easton Biopharmaceuticals Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chengdu Easton Biopharmaceuticals Co's EV-to-EBIT falls into.


SHSE:688513
95GF Score
Chengdu Easton Biopharmaceuticals Co Ltd SHSE:688513
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Chengdu Easton Biopharmaceuticals Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥287 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ¥287 Mil mean?
Chengdu Easton Biopharmaceuticals Co (SHSE:688513) has a EBIT of ¥287 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chengdu Easton Biopharmaceuticals Co.
Is Chengdu Easton Biopharmaceuticals Co's EBIT too high?
Chengdu Easton Biopharmaceuticals Co's current EBIT is ¥287 Mil. Overall, Chengdu Easton Biopharmaceuticals Co has a GF Score™ of 95/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chengdu Easton Biopharmaceuticals Co's EBIT compare to VRTX and REGN?
Chengdu Easton Biopharmaceuticals Co's EBIT of ¥287 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Chengdu Easton Biopharmaceuticals Co. Chengdu Easton Biopharmaceuticals Co's current EBIT is ¥287 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chengdu Easton Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co (SHSE:688513) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥47.90, compared to a current price of ¥52.66 — trading 9.9% above its estimated fair value. The current EBIT is ¥287 Mil. Chengdu Easton Biopharmaceuticals Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Chengdu Easton Biopharmaceuticals Co (SHSE:688513), the current EBIT is ¥287 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Chengdu Easton Biopharmaceuticals Co (SHSE:688513) Overvalued in 2026?

Based on GuruFocus' analysis, Chengdu Easton Biopharmaceuticals Co stock appears to be overvalued. The current stock price of ¥52.66 is trading 9.9% above its estimated GF Value™ of ¥47.90. GuruFocus considers Chengdu Easton Biopharmaceuticals Co to be Modestly Overvalued.

Key valuation signals for SHSE:688513:

  • EBIT: ¥287 Mil
  • GF Value™: ¥47.90 vs. price of ¥52.66 (9.9% above fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688513 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Chengdu Easton Biopharmaceuticals Co Business Description

Address No. 8, Xiyuan Avenue, Chengdu High-tech Zone, Sichuan Province, Chengdu, CHN, 611731
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
95GF Score

Get the complete analysis for SHSE:688513

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥52.66
Price
¥47.90
GF Value